Patient Square Capital LP
•CIK: 1819257•Filing: Q4 2025
**Patient Square Capital LP** manages $467M across a portfolio of 28 positions, exhibiting a concentrated focus on specialized healthcare and biotechnology opportunities. The fund's largest allocation is to PFG, representing $177.2M, followed by IM8N at $46.5M. Notable holdings also include significant positions in MIRM ($23.6M), ARGX ($21.9M), and ONC ($21.1M). This structure suggests a deep, conviction-driven approach within the life sciences sector.
Total AUM
$467.1M
QoQ Performance
+24.9%
Positions
28
Top 10 Concentration
77.5%
Latest Filing
Q4 2025
Top Holdings Allocation
ROIV
IM8N
MIRM
ROIV37.9%
IM8N9.9%
MIRM5.1%
ARGX4.7%
ONC4.5%
ABVX3.8%
PHARVARIS3.2%
EYPT3.1%
📈 Biggest Buys
📉 Biggest Sells
Sector Breakdown
Other100.0%
🚪 Exited Positionssold since Q3 2025
Changes from Q3 2025
NEW9 new positions
↑11 increased
↓7 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023